Drug Profile

AFX 5931

Alternative Names: AFX-5931

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Afecta Pharmaceuticals; LEO Pharma
Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies; Small molecules
Mechanism of Action Chemokine CCL2 modulators; Chemokine CCL5 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2025 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic)
26 Mar 2021 Discontinued - Phase-II for Eczema in USA (Topical) before March 2021 (Afecta Pharmaceuticals pipeline, March 2021)
26 Mar 2021 Preclinical trials in Diabetic retinopathy in USA (Ophthalmic) before March 2021 (Afecta Pharmaceuticals' pipeline, March 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com